A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF
The Japan Clinical Oncology Group (JCOG) previously conducted a randomized phase III trial
comparing irinotecan and cisplatin (IP) with EP in patients with extensive-stage SCLC. The
response rate and overall median survival were significantly better for IP, i.e. 84.4% and
12.8 months with IP, versus 67.5% and 9.4 months with EP, respectively. The 2-year survival
rates were 19.5% for IP and 5.2% for EP (7). These encouraging results prompted us to
explore the use of IP in LSCLC.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
during the study conduct
No
Yutaka Nishiwaki, MD
Study Chair
National Cancer Center Hospital East
Japan: Ministry of Health, Labor and Welfare
JCOG0202-MF
NCT00144989
September 2002
September 2011
Name | Location |
---|